Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis and haemostasis Jg. 107; H. 2; S. 253
Hauptverfasser: Fukuda, Toshio, Honda, Yuko, Kamisato, Chikako, Morishima, Yoshiyuki, Shibano, Toshiro
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Germany 01.02.2012
Schlagworte:
Administration, Oral
Animals
Anticoagulants - administration & dosage
Blood Coagulation Factors - administration & dosage
Factor VIIa - administration & dosage
Factor Xa Inhibitors
Hemorrhage - etiology
Hemorrhage - prevention & control
Hemostasis - drug effects
Humans
Male
Prothrombin Time
Pyridines - administration & dosage
Rats
Rats, Inbred Strains
Thiazoles - administration & dosage
ISSN:0340-6245, 2567-689X, 2567-689X
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of edoxaban at therapeutic and excess concentrations with the haemostatic agents, prothrombin complex concentrate (PPSB-HT), activated prothrombin complex concentrate (Feiba), and recombinant factor VIIa (rFVIIa). In rats, rFVIIa and Feiba was given during intensive anticoagulation with edoxaban. The haemostatic effect was evaluated in a model of planta template bleeding and a potential prothrombotic effect was evaluated in a venous thrombosis model. PPSB-HT, Feiba, and rFVIIa concentration-dependently shortened PT prolonged by edoxaban. Among these, rFVIIa and Feiba showed potent activities in reversing the PT prolongation by edoxaban. rFVIIa (1 and 3 mg/kg, i.v.) and Feiba (100 U/kg, i.v.) significantly reversed edoxaban (1 mg/kg/h)-induced prolongation of bleeding time in rats. In a rat venous thrombosis model, no potentiation of thrombus formation was observed when the highest dose (3 mg/kg) of rFVIIa was added to edoxaban (0.3 and 1 mg/kg/h) compared with the control. The present study indicated that rFVIIa, Feiba, and PPSB-HT have the potential to be reversal agents for edoxaban.
AbstractList Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of edoxaban at therapeutic and excess concentrations with the haemostatic agents, prothrombin complex concentrate (PPSB-HT), activated prothrombin complex concentrate (Feiba), and recombinant factor VIIa (rFVIIa). In rats, rFVIIa and Feiba was given during intensive anticoagulation with edoxaban. The haemostatic effect was evaluated in a model of planta template bleeding and a potential prothrombotic effect was evaluated in a venous thrombosis model. PPSB-HT, Feiba, and rFVIIa concentration-dependently shortened PT prolonged by edoxaban. Among these, rFVIIa and Feiba showed potent activities in reversing the PT prolongation by edoxaban. rFVIIa (1 and 3 mg/kg, i.v.) and Feiba (100 U/kg, i.v.) significantly reversed edoxaban (1 mg/kg/h)-induced prolongation of bleeding time in rats. In a rat venous thrombosis model, no potentiation of thrombus formation was observed when the highest dose (3 mg/kg) of rFVIIa was added to edoxaban (0.3 and 1 mg/kg/h) compared with the control. The present study indicated that rFVIIa, Feiba, and PPSB-HT have the potential to be reversal agents for edoxaban.
Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of edoxaban at therapeutic and excess concentrations with the haemostatic agents, prothrombin complex concentrate (PPSB-HT), activated prothrombin complex concentrate (Feiba), and recombinant factor VIIa (rFVIIa). In rats, rFVIIa and Feiba was given during intensive anticoagulation with edoxaban. The haemostatic effect was evaluated in a model of planta template bleeding and a potential prothrombotic effect was evaluated in a venous thrombosis model. PPSB-HT, Feiba, and rFVIIa concentration-dependently shortened PT prolonged by edoxaban. Among these, rFVIIa and Feiba showed potent activities in reversing the PT prolongation by edoxaban. rFVIIa (1 and 3 mg/kg, i.v.) and Feiba (100 U/kg, i.v.) significantly reversed edoxaban (1 mg/kg/h)-induced prolongation of bleeding time in rats. In a rat venous thrombosis model, no potentiation of thrombus formation was observed when the highest dose (3 mg/kg) of rFVIIa was added to edoxaban (0.3 and 1 mg/kg/h) compared with the control. The present study indicated that rFVIIa, Feiba, and PPSB-HT have the potential to be reversal agents for edoxaban.Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials. Therefore, agents to reverse the anticoagulant effects of edoxaban could be desirable in emergency situations. In this study, the reversal effects of haemostatic agents were determined on prothrombin time (PT) prolongation in vitro and bleeding time prolongation in vivo by edoxaban. PT using human plasma was measured in the presence of edoxaban at therapeutic and excess concentrations with the haemostatic agents, prothrombin complex concentrate (PPSB-HT), activated prothrombin complex concentrate (Feiba), and recombinant factor VIIa (rFVIIa). In rats, rFVIIa and Feiba was given during intensive anticoagulation with edoxaban. The haemostatic effect was evaluated in a model of planta template bleeding and a potential prothrombotic effect was evaluated in a venous thrombosis model. PPSB-HT, Feiba, and rFVIIa concentration-dependently shortened PT prolonged by edoxaban. Among these, rFVIIa and Feiba showed potent activities in reversing the PT prolongation by edoxaban. rFVIIa (1 and 3 mg/kg, i.v.) and Feiba (100 U/kg, i.v.) significantly reversed edoxaban (1 mg/kg/h)-induced prolongation of bleeding time in rats. In a rat venous thrombosis model, no potentiation of thrombus formation was observed when the highest dose (3 mg/kg) of rFVIIa was added to edoxaban (0.3 and 1 mg/kg/h) compared with the control. The present study indicated that rFVIIa, Feiba, and PPSB-HT have the potential to be reversal agents for edoxaban.
Author Shibano, Toshiro
Kamisato, Chikako
Honda, Yuko
Fukuda, Toshio
Morishima, Yoshiyuki
Author_xml – sequence: 1
  givenname: Toshio
  surname: Fukuda
  fullname: Fukuda, Toshio
  organization: Daiichi Sankyo Co., Ltd. – Biological Research Laboratories, Tokyo, Japan
– sequence: 2
  givenname: Yuko
  surname: Honda
  fullname: Honda, Yuko
– sequence: 3
  givenname: Chikako
  surname: Kamisato
  fullname: Kamisato, Chikako
– sequence: 4
  givenname: Yoshiyuki
  surname: Morishima
  fullname: Morishima, Yoshiyuki
– sequence: 5
  givenname: Toshiro
  surname: Shibano
  fullname: Shibano, Toshiro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22186946$$D View this record in MEDLINE/PubMed
BookMark eNo1kEtPwzAQhC1URB9w44x849KA7dhOfEQVUKRKSKhIvUWOs24NSVxih8e_JxXltLuaT6OdmaJR61tA6JKSG0oluV0vKU2ISoiU-QmaMCGzROZqM0ITknKSSMbFGE1DeCOESq7EGRozRnOpuJyg9xf4hC7oGnuLdRud8Xrb18OGwVowMRwEqPy3LnU7HxDsO13PceW6QcVWm-g7vNHYtTtXuuGY4y8Xd3inofEh6sES6y20MZyjU6vrABfHOUOvD_frxTJZPT8-Le5WiZGCxUSkJQMzxNAc8uEFk0lqUlUJq4nJZWqEZYIpVRoiDc9YKjKraZZxSEtuFWUzdP3nu-_8Rw8hFo0LBuohFfg-FIoqJbhKD-TVkezLBqpi37lGdz_Ffz_sFyIcaW4
CitedBy_id crossref_primary_10_1177_1753944718801554
crossref_primary_10_1586_14779072_2015_1053871
crossref_primary_10_1007_s11886_014_0480_9
crossref_primary_10_1160_TH12_06_0440
crossref_primary_10_1016_j_ncl_2013_03_001
crossref_primary_10_1007_s12185_016_1975_5
crossref_primary_10_1160_TH12_05_0319
crossref_primary_10_1093_bja_aes502
crossref_primary_10_1080_21548331_2015_998157
crossref_primary_10_1586_17474086_2015_1111756
crossref_primary_10_1007_s11239_013_0885_0
crossref_primary_10_1136_heartjnl_2012_301841
crossref_primary_10_1160_TH12_12_0907
crossref_primary_10_1016_j_hoc_2017_08_012
crossref_primary_10_3810_pgm_2013_01_2622
crossref_primary_10_1016_j_amjms_2016_03_018
crossref_primary_10_1007_s11910_014_0471_7
crossref_primary_10_1007_s11239_015_1185_7
crossref_primary_10_1016_j_thromres_2014_07_036
crossref_primary_10_1161_CIRCULATIONAHA_114_013445
crossref_primary_10_1016_j_thromres_2012_05_008
crossref_primary_10_1007_s11239_015_1297_0
crossref_primary_10_1007_s11239_021_02415_5
crossref_primary_10_1097_ALN_0000000000002910
crossref_primary_10_1016_j_thromres_2015_07_012
crossref_primary_10_1016_j_ijcard_2016_06_078
crossref_primary_10_1055_s_0040_1709134
crossref_primary_10_1080_21548331_2015_1103190
crossref_primary_10_1002_rth2_12089
crossref_primary_10_1038_nrcardio_2017_223
crossref_primary_10_1016_j_drudis_2014_05_013
crossref_primary_10_1186_s12959_015_0056_y
crossref_primary_10_1007_s00059_012_3616_y
crossref_primary_10_1161_STROKEAHA_118_023840
crossref_primary_10_1159_000484172
crossref_primary_10_1177_2042098613507945
crossref_primary_10_2215_CJN_02170218
crossref_primary_10_1055_s_0042_1753485
crossref_primary_10_1016_j_emc_2014_04_010
crossref_primary_10_1016_j_ajem_2014_08_075
crossref_primary_10_1111_jth_12830
crossref_primary_10_1182_blood_2013_09_529784
crossref_primary_10_1016_j_thromres_2013_03_016
crossref_primary_10_1016_j_cjca_2014_01_015
crossref_primary_10_1136_flgastro_2013_100325
crossref_primary_10_1097_MCC_0000000000000706
crossref_primary_10_1155_2015_920361
crossref_primary_10_1016_j_chest_2016_08_1462
crossref_primary_10_1016_j_ncl_2014_12_005
crossref_primary_10_2217_cer_15_15
crossref_primary_10_1517_17425255_2014_882897
crossref_primary_10_1002_phar_1532
crossref_primary_10_1016_j_jemermed_2012_12_022
crossref_primary_10_1016_j_beha_2013_07_001
crossref_primary_10_1016_j_jmv_2014_09_002
crossref_primary_10_1111_fcp_12091
crossref_primary_10_1007_s00264_019_04469_w
crossref_primary_10_1007_s12028_015_0222_x
crossref_primary_10_1136_svn_2019_000274
crossref_primary_10_1097_ALN_0000000000003899
crossref_primary_10_1016_j_thromres_2014_01_031
crossref_primary_10_1056_NEJMoa1310907
crossref_primary_10_1093_eurheartj_ehu181
crossref_primary_10_1016_j_hoc_2016_05_006
crossref_primary_10_1310_hpj5101_26
crossref_primary_10_1586_14779072_2015_987126
crossref_primary_10_1097_ACO_0000000000000100
crossref_primary_10_1007_s40256_016_0162_7
crossref_primary_10_1053_j_seminhematol_2014_02_002
crossref_primary_10_1097_PEC_0000000000002431
crossref_primary_10_1186_s13054_016_1413_3
crossref_primary_10_1016_j_jcin_2014_06_014
crossref_primary_10_4103_0022_3859_105448
crossref_primary_10_1097_ALN_0000000000000255
crossref_primary_10_1177_0897190012465989
crossref_primary_10_1016_j_thromres_2014_01_017
crossref_primary_10_1160_TH13_05_0431
crossref_primary_10_1177_0161734615617940
crossref_primary_10_1007_s11239_013_0958_0
crossref_primary_10_1016_j_trsl_2016_06_009
crossref_primary_10_1155_2016_1781684
crossref_primary_10_1002_mco2_23
crossref_primary_10_4137_CMC_S8204
crossref_primary_10_1016_S0049_3848_14_50026_6
crossref_primary_10_1179_2045772314Y_0000000230
crossref_primary_10_2217_fca_14_3
crossref_primary_10_1097_ALN_0000000000000520
crossref_primary_10_1186_s13054_016_1422_2
crossref_primary_10_1161_CIRCULATIONAHA_116_021831
crossref_primary_10_3810_hp_2013_02_1009
crossref_primary_10_1007_s11239_013_0967_z
crossref_primary_10_1007_s11239_015_1167_9
crossref_primary_10_1177_1074248414523675
crossref_primary_10_1007_s40256_015_0124_5
crossref_primary_10_1097_SHK_0000000000000848
crossref_primary_10_3810_hp_2014_12_1164
crossref_primary_10_1160_TH12_05_0298
crossref_primary_10_1007_s12325_012_0026_8
crossref_primary_10_1160_TH12_05_0330
crossref_primary_10_1016_j_drudis_2014_02_011
crossref_primary_10_1007_s40265_014_0261_1
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1160/TH11-09-0668
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 2567-689X
ExternalDocumentID 22186946
Genre Journal Article
GroupedDBID ---
.55
.GJ
0R~
0VX
123
1KJ
4.4
53G
5RE
AAQQT
ABJNI
ABOCM
ACGFO
ACGFS
ACNUY
AENEX
AFFNX
AGCGI
AHRSK
ALMA_UNASSIGNED_HOLDINGS
BR6
C45
CGR
CS3
CUY
CVF
DU5
EBS
ECM
EIF
EJD
F5P
H13
J5H
NPM
OVD
P2P
RTC
RTE
SJN
TEORI
X7M
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c652t-53b2ec567a4e8fecc761c39d5fa0c863c5f25299bc06c472357fa1774e3b4f912
IEDL.DBID 7X8
ISICitedReferencesCount 115
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000300748800007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0340-6245
2567-689X
IngestDate Fri Jul 11 06:26:18 EDT 2025
Mon Jul 21 05:51:59 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c652t-53b2ec567a4e8fecc761c39d5fa0c863c5f25299bc06c472357fa1774e3b4f912
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 22186946
PQID 919954931
PQPubID 23479
ParticipantIDs proquest_miscellaneous_919954931
pubmed_primary_22186946
PublicationCentury 2000
PublicationDate 2012-02-01
PublicationDateYYYYMMDD 2012-02-01
PublicationDate_xml – month: 02
  year: 2012
  text: 2012-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Thrombosis and haemostasis
PublicationTitleAlternate Thromb Haemost
PublicationYear 2012
SSID ssj0016495
Score 2.3991754
Snippet Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other anticoagulants in clinical trials....
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 253
SubjectTerms Administration, Oral
Animals
Anticoagulants - administration & dosage
Blood Coagulation Factors - administration & dosage
Factor VIIa - administration & dosage
Factor Xa Inhibitors
Hemorrhage - etiology
Hemorrhage - prevention & control
Hemostasis - drug effects
Humans
Male
Prothrombin Time
Pyridines - administration & dosage
Rats
Rats, Inbred Strains
Thiazoles - administration & dosage
Title Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents
URI https://www.ncbi.nlm.nih.gov/pubmed/22186946
https://www.proquest.com/docview/919954931
Volume 107
WOSCitedRecordID wos000300748800007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAMrDwEK_ykgfGRk1sx7EnhBBVB6gqVKRs0dlxRIVISlMQP59zkrIhBpYMTiJH9_Bdzt_5I-Q6UaGNczTekLM4EMZCYJhmAURJwgEDPkCj6YdkMlFpqqcdNqfuYJXrNbFZqPPK-hr5UPteYqF5dLN4DzxplN9c7Rg0NkmPYybjEV1J2nDQxej-Uul0DXWX4XA29sXApuVe_Z5ONmFltPfPD9onu10-SW9bAzggG648JK9PzqMtcLwqKIoOtQ2ecr5c0Q6_4W-4vPoCA-UAH6G-UX9A2wBHWxIemgKdly9zg06_HFBfsaUv4N4q34Q0txR8V1Z9RJ5H97O7cdCxKgRWxmwVxNwwZ1FAIJzCKW0iI8t1HhcQWiW5jQsWY5AyNpRWJP44nMJrTjhuRKEjdky2yqp0p4QCCBkZZUORY2JTWMOlAwVcFwn-9bmwT-hadBlard-KgNJVH3X2I7w-OWnFny3a0zUy1rBkCXn298vnZAfzF9aCqC9Ir0CPdZdk236u5vXyqrEGvE6mj98F78HI
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reversal+of+anticoagulant+effects+of+edoxaban%2C+an+oral%2C+direct+factor+Xa+inhibitor%2C+with+haemostatic+agents&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Fukuda%2C+Toshio&rft.au=Honda%2C+Yuko&rft.au=Kamisato%2C+Chikako&rft.au=Morishima%2C+Yoshiyuki&rft.date=2012-02-01&rft.issn=0340-6245&rft.volume=107&rft.issue=2&rft.spage=253&rft_id=info:doi/10.1160%2FTH11-09-0668&rft_id=info%3Apmid%2F22186946&rft_id=info%3Apmid%2F22186946&rft.externalDocID=22186946
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon